Skip to main content
H

HEXIMA LIMITED. — Investor Relations & Filings

Ticker · HXL ISIN · AU0000111932 ASX Professional, scientific and technical activities
Filings indexed 244 across all filing types
Latest filing 2022-07-20 Regulatory Filings
Country AU Australia
Listing ASX HXL

About HEXIMA LIMITED.

https://hexima.com.au/

Hexima Limited focuses on the research and development of plant-derived proteins for human therapeutic applications. The company's primary development candidate is pezadeftide (HXM163), a proprietary plant defensin formulated as a topical treatment for onychomycosis, a fungal nail infection. Pezadeftide is engineered to penetrate the nail plate and target underlying fungal pathogens. The company's technology platform utilizes the natural defense mechanisms of plants to develop novel antimicrobial and antifungal treatments. Originally focused on agricultural biotechnology, the company transitioned to human health to address unmet needs in dermatology. Its activities involve the clinical evaluation of protein-based therapies designed to offer improved efficacy and safety profiles compared to existing antifungal treatments.

Recent filings

Filing Released Lang Actions
Quarterly Activities Report and Appendix 4C - Jun-22 Qtr 7 pages 1.3MB
Regulatory Filings
2022-07-20 English
Phase II Results 3 pages 218.2KB
Regulatory Filings
2022-07-10 English
Phase II Preliminary Results 2 pages 167.7KB
Regulatory Filings
2022-06-23 English
ShareCafe Presentation 19 pages 1.3MB
Regulatory Filings
2022-04-28 English
Quarterly Activities Report and Appendix 4C 14 pages 2.9MB
Regulatory Filings
2022-04-28 English
Notification regarding unquoted securities - HXL 9 pages 32.5KB
Regulatory Filings
2022-04-27 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.